99.7% of people stayed HIV-negative while on
DESCOVY for PrEP® in a 2-year study

The DISCOVER trial recruited 5,000+ people. All study participants were either men or transgender women who have sex with men with diverse backgrounds and sexual practices who didn't always use condoms. Some participants had sexually transmitted infections.

The results were analyzed when everyone had been in the study for at least 2 years (~96 weeks), at that time:
99.7%
of people on DESCOVY stayed HIV-negative

8 out of 2670 people taking DESCOVY tested HIV-positive during the clinical study.*

99.4%
of people on TRUVADA®† stayed HIV-negative

15 out of 2665 people taking TRUVADA tested HIV-positive during the clinical study.‡

Common side effects in people taking DESCOVY for PrEP are diarrhea, nausea, headache, fatigue, and stomach pain. Tell your healthcare provider if you have any side effects that bother you or do not go away. Learn more about the possible side effects here.

In the study, PrEP medicines worked best when taken every day.

* 1 of these 8 people was suspected to have HIV before the study began.

† TRUVADA (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets.

‡ 4 of these 15 people were suspected to have HIV before the study began.

Ask your healthcare provider if DESCOVY for PrEP is right for you.